A critical evaluation of midazolam nasal spray for the treatment of patients with seizure clusters

References

• Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28:143–150.
   PubMed Web of Science ®Google Scholar
• Jafarpour S, Hirsch LJ, Gaínza-Lein M, et al. Seizure cluster: definition, prevalence, consequences, and management. Seizure. 2019;68:9–15.
   PubMed Web of Science ®Google Scholar
• McKee HR, Abou-Khalil B. Outpatient pharmacotherapy and modes of administration for acute repetitive and prolonged seizures. CNS Drugs. 2015;29:55–70.
   PubMed Web of Science ®Google Scholar
• Haut SR, Shinnar S, Moshé SL. Seizure clustering: risks and outcomes. Epilepsia. 2005;46:146–149.
   PubMed Web of Science ®Google Scholar
• Chen B, Choi H, Hirsch LJ, et al. Prevalence and risk factors of seizure clusters in adult patients with epilepsy. Epilepsy Res. 2017;133:98–102.
   PubMed Web of Science ®Google Scholar
• Detyniecki K, O’Bryan J, Choezom T, et al. Prevalence and predictors of seizure clusters: a prospective observational study of adult patients with epilepsy. Epilepsy Behav. 2018;88:349–356.
   PubMed Web of Science ®Google Scholar
• Sillanpää M, Schmidt D. Seizure clustering during drug treatment affects seizure outcome and mortality of childhood-onset epilepsy. Brain. 2008;131:938–944.
   PubMed Web of Science ®Google Scholar
• Fraga V, Falip M, Donaire A, et al. Experience with buccal midazolam for seizure clusters in adults. Epilepsia. 2014;55:119. (abstract p359).
   Google Scholar
• Vazquez B, Hesdorffer D, Wu E, et al. Association of rescue medication use with clinical outcomes and health care costs in patients with seizure clusters. J Manag Care Specialty Pharmacy. 2016;22:S78–9. (abstract G49).
   Google Scholar
• Penovich PE, Buelow J, Steinberg K, et al. Burden of seizure clusters on patients with epilepsy and caregivers: survey of patient, caregiver, and clinician perspectives. Neurologist. 2017;22:207–214.
   PubMed Web of Science ®Google Scholar
• Reick-Mitrisin V, Bertran L, Hupp N, et al. The impact of generalized tonic clonic seizure clusters. Epilepsia. 2018;59:S344. (abstract p753).
   Web of Science ®Google Scholar
• Bauer J, Burr W. Course of chronic focal epilepsy resistant to anticonvulsant treatment. Seizure. 2001;10:239–246.
   PubMed Web of Science ®Google Scholar
• Haut SR, Lipton RB, LeValley AJ, et al. Identifying seizure clusters in patients with epilepsy. Neurology. 2005;65:1313–1315.
   PubMed Web of Science ®Google Scholar
• Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009;87:137–143.
   PubMed Web of Science ®Google Scholar
• Shafer P, Fisher R, Bartfeld E. Using an online epilepsy diary to enhance self-management behaviors of people with epilepsy. 64th American Epilepsy Society Annual Meeting; December 2–6; San Antonio, TX; 2010 (abstract 2.025).
   Google Scholar
• Fisher RS, Bartfeld E, Cramer JA. Use of an online epilepsy diary to characterize repetitive seizures. Epilepsy Behav. 2015;47:66–71.
   PubMed Web of Science ®Google Scholar
• Jafarpour S, O’Bryan J, Lewis S, et al. Seizure clusters in pediatric epilepsy: the Harvard-Yale pediatric epilepsy cluster study. 72nd American Epilepsy Society Annual Meeting; November 30–December 4; New Orleans, LA; 2018 (abstract 1.194).
   Google Scholar
• Sinha S, Satishchandra P, Kalband BR, et al. New-onset status epilepticus and cluster seizures in the elderly. J Clin Neurosci. 2013;20:423–428.
   PubMed Web of Science ®Google Scholar
• Herzog AG. Catamenial epilepsy: definition, prevalence pathophysiology and treatment. Seizure. 2008;17:151–159.
   PubMed Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–1077.
   PubMed Web of Science ®Google Scholar
• Kalilani L, Sun X, Pelgrims B, et al. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59:2179–2193.
   PubMed Web of Science ®Google Scholar
• Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66:821–825.
   PubMed Web of Science ®Google Scholar
• Komaragiri A, Detyniecki K, Hirsch LJ. Seizure clusters: a common, understudied and undertreated phenomenon in refractory epilepsy. Epilepsy Behav. 2016;59:83–86.
   PubMed Web of Science ®Google Scholar
• Divino V, Petrilla AA, Bollu V, et al. Clinical and economic burden of breakthrough seizures. Epilepsy Behav. 2015;51:40–47.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs I: treatment of new-onset epilepsy. Neurology. 2018;91:74–81.
   PubMed Web of Science ®Google Scholar
• Kanner AM, Ashman E, Gloss D, et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy. Neurology. 2018;91:82–90.
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and management. CG137. 2012. [cited 2020 Feb 17]. Available from: www.nice.org.uk/guidance/cg137
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of epilepsy in adults. SIGN 143. 2015. [cited 2020 Feb 17]. Available from: https://www.sign.ac.uk/sign-143-diagnosis-and-management-of-epilepsy-in-adults.html
   Google Scholar
• Ma L, Yung A, Yau E, et al. Clinical guidelines on management of prolonged seizures, serial seizures and convulsive status epilepticus in children. HK J Paediatr (New Series). 2010;15:52–63.
   Web of Science ®Google Scholar
• Terry D, Paolicchi J, Karn M. Acceptance of the use of diazepam rectal gel in school and day care settings. J Child Neurol. 2007;22:1135–1138.
   PubMed Web of Science ®Google Scholar
• Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164:747–753.
   PubMedGoogle Scholar
• Wilson MT, Macleod S, O’Regan ME. Nasal/buccal midazolam use in the community. Arch Dis Child. 2004;89:50–51.
   PubMed Web of Science ®Google Scholar
• Gainza-Lein M, Benjamin R, Stredny C, et al. Rescue medications in epilepsy patients: a family perspective. Seizure. 2017;52:188–194.
   PubMed Web of Science ®Google Scholar
• Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.
   PubMed Web of Science ®Google Scholar
• de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010;51:478–482.
   PubMed Web of Science ®Google Scholar
• Kadel J, Bauer S, Hermsen AM, et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs. 2018;32:771–781.
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Heller AH. Diazepam buccal film for the treatment of acute seizures. Epilepsy Behav. 2019;101:106537.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR for the public. Buccolam midazolam. 2011.[cited 2020 Feb 17]. Available from: https://www.ema.europa.eu/en/documents/overview/buccolam-epar-summary-public_en.pdf
   Google Scholar
• French JA, Wechsler R, Gelfand MA, et al. Inhaled alprazolam rapidly suppresses epileptic activity in photosensitive participants. Epilepsia. 2019;60:1602–1609.
   PubMed Web of Science ®Google Scholar
• Mula M. New non-intravenous routes for benzodiazepines in epilepsy: a clinician perspective. CNS Drugs. 2017;31:11–17.
   PubMed Web of Science ®Google Scholar
• Meridian Medical Technologies I. Seizalam™ prescribing information. 2018. [cited 2020 Aug 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209566Orig1s000lbl.pdf
   Google Scholar
• Veriton Pharma Ltd. Epistatus® summary of product characteristics. 2019. [cited 2020 Aug 21]. Available from: https://www.epistatus.co.uk/downloads/epistatus_summary_of_product_characteristics.pdf
   Google Scholar
• Shire Services BVBA. BUCCOLAM summary of product characteristics. 2019. [cited 2020 Aug 20]. Available from: https://www.ema.europa.eu/en/documents/product-information/buccolam-epar-product-information_en.pdf
   Google Scholar
• UCB, Inc. NAYZILAM® (midazolam) nasal spray, CIV US prescribing information. 2019. [cited 2020 Feb 17]. Available from: https://www.ucb-usa.com/_up/ucb_usa_com_kopie/documents/Nayzilam_PI.pdf
   Google Scholar
• National Center for Biotechnology Information. PubChem Database. Midazolam, CID=4192. 2019. [cited 2020 Feb 17]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Midazolam
   Google Scholar
• Neurelis, Inc. VALTOCO® (diazepam nasal spray), CIV US Prescribing Information 2020. [cited 2020 Feb 17]. Available from: https://www.valtoco.com/sites/default/files/VALTOCO_Prescribing_Information.pdf
   Google Scholar
• Osborne Shafer P. New drug: Valtoco (diazepam nasal spray) approved as rescue therapy for seizures. 2020. [cited 2020 Mar 21]. Available from: https://www.epilepsy.com/article/2020/1/new-drug-valtoco-diazepam-nasal-spray-approved-rescue-therapy-seizures
   Google Scholar
• Bouw MR, Chung SS, Gidal B, et al. Clinical pharmacokinetic and pharmacodynamic profile of midazolam nasal spray. Epilepsy Res. 2021 Feb 3;171:106567.
   PubMed Web of Science ®Google Scholar
• Sheckler MT, Mermelstein F, Hamilton DA, et al. Nasal delivery of analgesics. Nasal drug delivery: rapid onset via a convenient route. 2005. [cited 2020 Jun 11]. Available from: https://www.ondrugdelivery.com/wp-content/uploads/2018/11/Nov2005.pdf
   Google Scholar
• Sieghart W, Savić MM. International Union of Basic and Clinical Pharmacology. CVI: GABA(A) receptor subtype- and function-selective ligands: key issues in translation to humans. Pharmacol Rev. 2018;70:836–878.
   PubMed Web of Science ®Google Scholar
• Hardmeier M, Zimmermann R, Ruegg S, et al. Intranasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. Clin Pharmacol Ther. 2012;91:856–862.
   PubMed Web of Science ®Google Scholar
• Kay L, Merkel N, von Blomberg A, et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neurol. 2019;6:2413–2425.
   PubMedGoogle Scholar
• Berg AK, Myrvik MJ, Van Ess PJ. Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: randomized study in healthy geriatric and non-geriatric adults. Epilepsy Behav. 2017;71:51–59.
   PubMed Web of Science ®Google Scholar
• Detyniecki K, Van Ess PJ, Sequeira DJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters - a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60:1797–1808.
   PubMed Web of Science ®Google Scholar
• Detyniecki K, Campos R, Gasalla T, et al. Somnolence and time to return to baseline functionality after midazolam nasal spray delivery in patients with seizure clusters: post hoc analysis of a randomized, double-blind, placebo-controlled trial. 73rd American Epilepsy Society Annual Meeting; December 6–10; Baltimore, MD; 2019 (abstract 2.243).
   Google Scholar
• Wheless JW, Meng TC, Van Ess PJ, et al. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: an open-label extension trial. Epilepsia. 2019;60:1809–1819.
   PubMed Web of Science ®Google Scholar
• United States Drug Enforcement Administration. Drug scheduling. [cited 2020 Feb 26]. Available from: https://www.dea.gov/drug-scheduling
   Google Scholar
• Szeto I, Meng TC, Van Ess PJ. Abuse liability of midazolam nasal spray (MDZ-NS) in adult recreational benzodiazepine users: phase 1, randomized, double-blind, double-dummy, active- and placebo-controlled, crossover trial. 73rd American Epilepsy Society Annual Meeting December 6–10; Baltimore, MD; 2019 (abstract 3.330).
   Google Scholar
• Berg A, Bancke L, Kapelan B, et al. Pharmacokinetics of midazolam nasal spray in pediatric subjects with epilepsy. 70th American Epilepsy Society Annual Meeting; December 2–6; Houston, TX; 2016 (abstract 2.196).
   Google Scholar
• Bancke L, Berg A, Kapelan B, et al. Pharmacokinetics, safety, and tolerability of midazolam nasal spray (USL261) in pediatric subjects with epilepsy. Ann Neurol. 2016;80:S324–5. (abstract 52).
   Web of Science ®Google Scholar
• Floyd MD, Gervasini G, Masica AL, et al. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics. 2003;13:595–606.
   PubMedGoogle Scholar
• Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79:362–370.
   PubMed Web of Science ®Google Scholar
• Sun GC, Hsu MC, Chia YY, et al. Effects of age and gender on intravenous midazolam premedication: a randomized double-blind study. Br J Anaesth. 2008;101:632–639.
   PubMed Web of Science ®Google Scholar
• Bancke L, Meng T-C, Kapelan B, et al. Tolerability of midazolam nasal spray in pediatric subjects with epilepsy. 70th American Epilepsy Society Annual Meeting; December 2–6; Houston, TX; 2016 (abstract 2.197).
   Google Scholar
• Kay L, Reif PS, Belke M, et al. Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia. 2015;56:1408–1414.
   PubMed Web of Science ®Google Scholar
• von Blomberg A, Kay L, Knake S, et al. Efficacy, tolerability, and safety of concentrated intranasal midazolam spray as emergency medication in epilepsy patients during video-EEG monitoring. CNS Drugs. 2020;34:545–553.
   PubMed Web of Science ®Google Scholar
• Mula M. The safety and tolerability of intranasal midazolam in epilepsy. Expert Rev Neurother. 2014;14:735–740.
   PubMed Web of Science ®Google Scholar
• Drugs.com. FDA approves Nayzilam (midazolam) Nasal Spray to treat seizure clusters. 2019. [cited 2020 Feb 18]. Available from: https://www.drugs.com/newdrugs/fda-approves-nayzilam-midazolam-nasal-seizure-clusters-4977.html
   Google Scholar
• United States Food and Drug Administration. Drugs@FDA: FDA-approved drugs. [cited 2020 Mar 31]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211321
   Google Scholar
• Hantus S. Epilepsy emergencies. Continuum (Minneapolis, Minn). 2016;22:173–190.
   PubMedGoogle Scholar
• Midazolam injection, USP [package insert]. Lake Zurich, IL, USA: Fresenius Kabi; 2017.
   Google Scholar
• Shorvon S. Clinical trials in acute repetitive seizures and status epilepticus. Epileptic Disord. 2012;14:138–147.
   PubMed Web of Science ®Google Scholar
• Prolonged epileptic seizures: identification and rescue treatment strategies. Epileptic Disord. 2014. [cited 2020 Aug 17]. Available from: https://www.ilae.org/files/dmfile/EpD_Vol-16_Suppl-1_Prolonged-Epileptic_Seizures.pdf
   Google Scholar
• American Epilepsy Society. Clinical resources. [cited 2020 Aug 17]. Available from: https://www.aesnet.org/clinical_resources
   Google Scholar
• National Institute of Neurological Disorders and Stroke. Epilepsy information page. [cited 2020 Aug 17]. Available from: https://www.ninds.nih.gov/Disorders/All-Disorders/Epilepsy-Information-Page
   Google Scholar